BetterLife Pharma (BETRF) Stock Price, News & Analysis

Company Overview

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.07 to $0.10
• 52-Week Range: $0.03 to $0.15
• Volume: 1,059 shs
• Average Volume: 10,934 shs
• Market Capitalization: $9.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BetterLife Pharma Stock Analysis - MarketRank™

BetterLife Pharma scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BetterLife Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BetterLife Pharma is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BetterLife Pharma is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the outstanding shares of BetterLife Pharma have been sold short.

Short Interest Ratio / Days to Cover

BetterLife Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BetterLife Pharma has recently increased by 22,100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BetterLife Pharma does not currently pay a dividend.

Dividend Growth

BetterLife Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the outstanding shares of BetterLife Pharma have been sold short.

Short Interest Ratio / Days to Cover

BetterLife Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BetterLife Pharma has recently increased by 22,100.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BetterLife Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BetterLife Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.77% of the stock of BetterLife Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.01% of the stock of BetterLife Pharma is held by institutions.

BETRF Stock Analysis - Frequently Asked Questions

How have BETRF shares performed this year?

BetterLife Pharma's stock was trading at $0.0480 on January 1st, 2024. Since then, BETRF shares have increased by 50.2% and is now trading at $0.0721.
View the best growth stocks for 2024 here.

How were BetterLife Pharma's earnings last quarter?

BetterLife Pharma Inc. (OTCMKTS:BETRF) issued its quarterly earnings results on Wednesday, September, 25th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of BetterLife Pharma?

Shares of BETRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 9/25/2024
• Today: 11/21/2024
• Fiscal Year End: 1/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BETRF
• CUSIP: N/A
• CIK: 1464165
• Web: www.abetterlifepharma.com
• Phone: 604-221-0595
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,140,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -998.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.05) per share
• Price / Book: -1.44

Miscellaneous

• Outstanding Shares: 129,460,000
• Free Float: 84,449,000
• Market Cap: $9.33 million
• Optionable: Not Optionable
• Beta: 1.27